50 Mio $ in bar und Blockbuster Krebsmittel in Phase 3 Top Ergebnissen und Pipeline voll.....Let's - 500 Beiträge pro Seite

[sunny3999]

Am 11 März 2010 präsentiert CEO J. Lewis auf der Cowen and Company in Boston vor.

http://www.businesswire.com/portal/site/home/permalink/?ndmV…

NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the Cowen and Company 30th Annual Health Care Conference on Thursday, March 11, 2010 at 11:05 am at the Boston Marriott Copley Place in Boston, MA. Dr. Lewis will provide an overview of the Company and its clinical development programs.

Hierzu ein 18 seitiger Bericht:

http://www.mikehavrx.com/blog/bid/17115/Griffin-Securities-R…

Link klicken Click here to view or download the full 18-page PDF report.

Die drei mit einer konservativen Bewertung für Ziopharm mit 7-8 $:

R&R - Jan 18th,2010 - Buy with 12-month target of $8
JMP - Feb 18th, 2010 - Buy with 12-month target of $7
Griffin - March 4th, 2010 - Buy with a 12-month target of $8

http://www.clinicaltrials.gov/ct2/results/map?term=ziopharm


weitere interessanter Link: http://seekingalpha.com/article/177858-ziopharm-the-money-s-…

Knapp 42 Mio (50% in festen Händen) Shares bei 155 Mio$ MK davon

[jeffjass]

06.04.2010 14:40
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors

-- Dr. Murray Brennan Named Chairman of Board --

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today the appointment of George B. Abercrombie to its Board of Directors. Mr. Abercrombie will serve as a member of the Board's Compensation Committee as well as the Nominating and Corporate Governance Committee. Additionally, Dr. Murray Brennan was elected Chairman of the Board.

Mr. Abercrombie most recently served as the President and Chief Executive Officer of Hoffmann-La Roche (Roche) North America and has more than 30 years experience in the pharmaceutical industry. He was responsible for Roche's U.S. and Canadian Pharmaceuticals Business. Under Mr. Abercrombie's leadership, the value of Roche's U.S. business increased, achieving leading market share positions for key marketed products. In joining the ZIOPHARM board, George will also have the opportunity to continue his relationship with Dr. Larry Norton, a consultant partner to ZIOPHARM, with whom he worked closely at Roche and while Dr. Norton was the president of ASCO. Prior to joining Hoffmann-La Roche Inc. in 2001, Mr. Abercrombie held the position of Senior Vice President, Commercial Operations at Glaxo Wellcome Inc. and prior to joining Glaxo, held progressively senior positions at Merck and Company in Merck's Human Health Division in the United States.

During his distinguished career he has testified as an expert witness on numerous occasions in front of both Houses of the U.S. Congress. Mr. Abercrombie began his career as a pharmacist after receiving a bachelor's degree in pharmacy from the University of North Carolina and earned his MBA from Harvard University. He has served on many boards and organizations throughout his career, including the PhRMA (Pharmaceutical Research and Manufacturers of America) Board of Directors, the Johns Hopkins School of Hygiene and the Public Health Advisory, Project Hope Board of Directors, and the Duke University Fuqua School of Business Health Sector Advisory Board, among others.

"Given George's extensive knowledge and understanding of the development and commercialization of pharmaceutical products across a wide range of indications, including those for cancer-related therapies, he will be an invaluable addition to the ZIOPHARM team," stated Dr. Murray Brennan, Chairman of the Board. "ZIOPHARM will no doubt benefit from George's wisdom and experience and we are extremely pleased to have him on board at this important transformational stage of the Company's growth and development."

"This is really an exciting time for ZIOPHARM and me. I am thrilled to be joining this team of enormously impressive professionals who are developing promising medicines to treat cancer," commented Mr. Abercrombie. "I look forward to contributing to ZIOPHARM's success as we build value for patients, shareholders, and the healthcare system."

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.

Palifosfamide (ZymafosTM or ZIO-201) references a novel composition (tris formulation) that comprises the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used DNA-alkylating drugs used to treat cancers. Palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. It may also have other advantages. Intravenous palifosfamide is currently in a randomized Phase II trial to treat unresectable or metastatic soft tissue sarcoma in the front- and second-line setting with the Company having reported interim positive results in late 2009; a registration trial in the same setting is expected to initiate following U.S. Food and Drug Administration (FDA) review in the first half of this year. An oral form of palifosfamide has been developed preclinically to the investigational new drug application stage.

Darinaparsin (ZinaparTM or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. The Company has reported favorable results from a Phase II trial with IV-administered darinaparsin in lymphoma, particularly peripheral T-cell lymphoma ("PTCL"), at the American Society of Clinical Oncology (ASCO) in May of 2009 which would serve as the basis for ongoing clinical study in PTCL following regulatory review and available financial resources Phase I trials with the oral form are ongoing in both hematological malignancies and solid tumors.

Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. In addition, indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I trials in cancer patients, oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. Most recently, results of oral indibulin in combination with oral capecitabine (Xeloda®) were presented at last year's American Society of Clinical Oncology (ASCO) along with the preclinical findings of a novel dosing schedule conducted under the direction of Dr. Larry Norton; employing this dosage schedule, the Company expects to initiate a Phase I study early this year in breast cancer patients with the breast team at Memorial Sloan Kettering.

ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.

ZIOP-G

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, the risk that pre-clinical or clinical trials will proceed on schedules that are consistent with the Company's current expectations or at all, risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company's ability to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Contacts:

ZIOPHARM Oncology, Inc.
Tyler Cook, 617-259-1982
[e-mail]
or
Media:
Dennis S. Dobson, 203-258-0159
[e-mail]


© 2010 Business Wire

[jeffjass]

08.04.2010 14:36
ZIOPHARM Commences Oral Indibulin Phase I/II Trial in Breast Cancer -- at Memorial Sloan-Kettering Cancer Center --

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today it has initiated a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of oral indibulin (Zybulin™ or ZIO-301) in the treatment of metastatic breast cancer.

The Phase I trial is expected to enroll approximately 20 patients and will determine the maximum tolerated dose of oral indibulin implementing the "mathematically modeled" dose administration schedule - 5 days on and 9 days off - that capitalizes on the convenience of oral administration, but also maximizes drug activity, limiting potential toxicity and resistance.

Indibulin is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. It is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy, and minimal overall toxicity. In multiple Phase I trials, oral indibulin has been administered both as a single agent and in combination with favorable activity, and has a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. The trial will be continued into Phase II once dose has been established in Phase I.

Clifford A. Hudis, M.D., Chief of the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center, noted, "The development of an additional new therapy for breast cancer that is effective but with fewer of the more significant side effects associated with many commonly used therapies would be an important step in the treatment of this disease. We look forward to testing this novel agent and dosing schedule in patients."

The study will implement a mathematically modeled drug administration schedule that was developed in preclinical studies by Larry Norton, M.D. as a consultant to ZIOPHARM Oncology, Inc. The model capitalizes on the convenience and scheduling flexibility of oral administration to maximize anticancer activity, minimize potential toxicity and resistance, and exploit the drug's mechanisms of action on both cancer cell division and cell movement. Findings from the preclinical studies were presented at the 2009 American Society of Clinical Oncology annual meeting.

Memorial Sloan-Kettering's Breast Cancer Medicine team, under the direction of Dr. Hudis, has successfully translated preclinical work into meaningful clinical treatment in past studies, and will lead this Phase I/II trial.

For more details about this trial, please see www.clinicaltrials.gov.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.

Palifosfamide (ZymafosTM or ZIO-201) references a novel composition (tris formulation) that comprises the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used DNA-alkylating drugs used to treat cancers. Palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. It may also have other advantages. Intravenous palifosfamide is currently in a randomized Phase II trial to treat unresectable or metastatic soft tissue sarcoma in the front- and second-line setting with the Company having reported interim positive results in late 2009; a registration trial in the same setting is expected to initiate following U.S. Food and Drug Administration (FDA) review in the first half of this year. An oral form of palifosfamide has been developed preclinically to the investigational new drug application stage.

Darinaparsin (ZinaparTM or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. The Company has reported favorable results from a Phase II trial with IV-administered darinaparsin in lymphoma, particularly peripheral T-cell lymphoma ("PTCL"), at the American Society of Clinical Oncology (ASCO) in May of 2009 which would serve as the basis for ongoing clinical study in PTCL following regulatory review and available financial resources. Phase I trials with an oral form are ongoing in both hematological malignancies and solid tumors.

Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. In addition, indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I trials in cancer patients, oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. Results of oral indibulin in combination with oral capecitabine (Xeloda®) were presented at last year's American Society of Clinical Oncology (ASCO) along with the preclinical findings of a novel dosing schedule conducted under the direction of Dr. Larry Norton. Employing this dosage schedule, the Company has initiated a Phase I study in breast cancer patients with the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center.

ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.

ZIOP-G

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company's ability to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Contacts:

ZIOPHARM Oncology, Inc.
Tyler Cook, 617-259-1982
[e-mail]
or
Media:
Dennis S. Dobson, 203-258-0159
[e-mail]


© 2010 Business Wire

[sunny3999]

Zur Zeit wenig Käufer zuviel Verkäufer vielleicht ist die Aktie heiß gelaufen.

Sicher ist sicher Gewinne mitnehmen schadet nie ob das Target von 8-9 $erreicht wird ? Nur meine Meinung hat nix zu sagen und muß jeder für sich entscheien!

http://www.mffais.com/ziop

[sunny3999]

Antwort auf Beitrag Nr.: 39.332.650 von sunny3999 am 14.04.10 14:30:59

Obwohl dieser Fund haben am 09.04. gekauft:
iShares Russell Microcap Index 68,469 -1,472 0.18 0.09 04/09/2010

Instis:
Qvt Financial Lp. 3,871,000 3,871,000 12.87 0.53 12/31/2009
Awm Investment Company Inc 2,013,973 1,618,830 7.88 0.77 12/31/2009
Great Point Partners Llc 1,613,000 1,613,000 6.31 3.23 12/31/2009
Millennium Management LLC 1,444,683 616,600 5.65 0.05 12/31/2009
Exis Capital Management Inc 1,328,400 1,328,400 5.19 3.25 12/31/2009
BlackRock Advisors (UK) Ltd 656,083 49,814 2.57 0.02 12/31/2009
Baker Bros Advisors Llc 645,000 645,000 2.52 0.13 12/31/2009
Medical Strategy GmbH 372,315 191,388 1.44 1.07 02/28/2010
Perceptive Advisors LLC 350,000 350,000 1.37 0.24 12/31/2009
First New York Securities LLC 273,392 273,392 1.07 0.19 12/31/2009

Total: Top 10 Institutions 12,567,846 10,557,424 46.87

[sunny3999]

57 % seit Threaderöffnung in knapp 2 Monaten !

[jeffjass]

http://www.rttnews.com/ArticleView.aspx?Id=1277764

[jeffjass]

30.04.2010 14:35
ZIOPHARM Reports First Quarter Financial Results

Decreased Cash Burn from Operations, Continued Clinical Progress

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that is seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, today reported its financial results for the three months ended March 31, 2010 and updated the Company's continued progress with its clinical programs.

In the first quarter of 2010, the Company's cash burn from operations was $3.8 million, a decrease of $0.8 million from $4.6 million for the same period for 2009. The spending decrease represents a continued focus of resources as well as tight management of operating expenses. The Company ended the March 2010 quarter with cash of approximately $45.0 million. The Company expects its existing cash resources to support operations early into the first quarter of 2012, although this expectation could change based on, among other things, the scope and timing for the Company's registration trial for palifosfamide.

The net loss from operations for the first quarter of 2010 was $4.6 million, or $(0.11) per share, compared with a net loss from operations for the first quarter of 2009 of $3.3 million, or $(0.16) per share. In the first quarter of 2010, there was a $13.1 million non-cash charge for the change in the fair value of warrants arising from the increase in the Company's stock price, resulting in a total net loss for the first quarter of $17.7 million, or $(0.44) per share, compared with a net loss for the first quarter of 2009 of $3.3 million, or $(0.16) per share. The warrant charge relates to fair value accounting which requires the warrants to be marked to market under accounting principles generally accepted in the United States.

Research and development expenses in the first quarter of 2010 increased $0.3 million while general and administrative expenses increased by $0.9 million. The increased general and administrative activity during the first three months of 2010 was related to administrative support in preparation for new clinical studies not yet initiated.

Progress for all three of the Company's clinical-stage compounds continues to advance. Palifosfamide (ZymafosTM or ZIO-201) has been recognized with acceptance for presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting in June. It has also been selected to be included in the 2010 Best of ASCO®. The Best of ASCO® program features selected important abstracts that highlight the latest scientific findings and practice-changing advances in cancer prevention and treatment, allowing faculty members to provide a clinical context for this new scientific information. Meetings are conducted in both Boston and San Francisco as well as in many international cities. The Company expects to initiate a worldwide palifosfamide Phase III registration trial as early as the first half of this year.

Also during the first quarter, the Company initiated a Phase I/II study of indibulin (ZybulinTM or ZIO-301) at Memorial Sloan-Kettering Cancer Center for the novel, mathematically - determined administration of indibulin in the treatment of metastatic breast cancer. With regard to darinaparsin (ZinaparTM, or ZIO-101), the Company recently presented preclinical data at the 2010 AACR Annual Meeting and the Phase I clinical studies of the oral form of the drug are continuing while the Company moves to a potential pathway for regulatory approval of the intravenous form in peripheral T-cell lymphoma.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.

Palifosfamide (ZymafosTM or ZIO-201) references a novel composition (tris formulation) that comprises the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used DNA-alkylating drugs used to treat cancers. Palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. It may also have other advantages. Intravenous palifosfamide is currently in a randomized Phase II trial to treat unresectable or metastatic soft tissue sarcoma in the front- and second-line setting with the Company having reported interim positive results in late 2009; a registration trial in the same setting is expected to initiate following U.S. Food and Drug Administration (FDA) review in the first half of this year. An oral form of palifosfamide has been developed preclinically to the investigational new drug application stage.

Darinaparsin (ZinaparTM or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. The Company has reported favorable results from a Phase II trial with IV-administered darinaparsin in lymphoma, particularly peripheral T-cell lymphoma ("PTCL"), at the American Society of Clinical Oncology (ASCO) in May of 2009 which would serve as the basis for ongoing clinical study in PTCL following regulatory review and available financial resources. Phase I trials with the oral form are ongoing in both hematological malignancies and solid tumors.

Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. In addition, indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I trials in cancer patients, oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. Most recently, results of oral indibulin in combination with oral capecitabine (Xeloda®) were presented at last year's American Society of Clinical Oncology (ASCO) along with the preclinical findings of a novel dosing schedule conducted under the direction of Dr. Larry Norton; employing this dosage schedule, the Company has initiated a Phase I study in breast cancer patients with the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center.

ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.

ZIOP-E

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, the risk that pre-clinical or clinical trials will proceed on schedules that are consistent with the Company's current expectations or at all, risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company's ability to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.
ZIOPHARM Oncology, Inc.
Condensed Statements of Operations
(in thousands except share and per share data)

Three Months Ended
March 31,
(unaudited)
2010 2009

Research contract revenue $ - $ -

Operating expenses:

Research and development, including
costs of research contracts
1,939 1,608
General and administrative 2,630 1,724
Total operating expenses 4,569 3,332

Loss from operations (4,569 ) (3,332 )

Other income (expense), net 9 -
Change in fair value of warrants (13,093 ) (7 )
Net income (loss) $ (17,653 ) $ (3,339 )


Basic and diluted net income (loss) per share $ (0.44 ) $ (0.16 )


Weighted average common shares outstanding used
to compute basic and diluted net income (loss) per share
40,150,100 21,304,334
ZIOPHARM Oncology, Inc.
Balance Sheet Data
(in thousands)

March 31, December 31,
2010 2009
(unaudited) (unaudited)

Cash and cash equivalents 45,044 48,839
Working capital 42,523 46,098
Total assets 45,840 49,736
Total stockholders' equity 11,386 28,104

Contacts:

ZIOPHARM Oncology, Inc.
Tyler Cook, 617-259-1982
[e-mail]
or
Media:
Dennis S. Dobson, 203-258-0159
[e-mail]



© 2010 Business Wire

[jeffjass]

04.05.2010 14:57
ZIOPHARM Oncology to Present at the Ninth Annual JMP Securities Research Conference

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan Lewis, MD, PhD, Chief Executive Officer, will present at the Ninth Annual JMP Securities Research Conference on Monday, May 11, 2010 at 9:30 am PT at The Ritz-Carlton, San Francisco. Dr. Lewis will provide an overview of the Company and its clinical development programs.

To access the live audio webcast, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for ninety days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.

Palifosfamide (ZymafosTM or ZIO-201) references a novel composition (tris formulation) that comprises the functional active metabolite of ifosfamide, a standard of care for treating sarcoma, lymphoma, testicular, and other cancers. Palifosfamide delivers only the cancer fighting component of ifosfamide. It is expected to overcome the resistance seen with ifosfamide and cyclophosphamide, two of the most commonly used DNA-alkylating drugs used to treat cancers. Palifosfamide does not have the toxic metabolites of ifosfamide that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. It may also have other advantages. Intravenous palifosfamide is currently in a randomized Phase II trial to treat unresectable or metastatic soft tissue sarcoma in the front- and second-line setting with the Company having reported interim positive results in late 2009; a registration trial in the same setting is expected to initiate following U.S. Food and Drug Administration (FDA) review in the first half of this year. An oral form of palifosfamide has been developed preclinically to the investigational new drug application stage.

Darinaparsin (ZinaparTM or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less toxic than inorganic arsenic, particularly with regard to cardiac toxicity. The Company has reported favorable results from a Phase II trial with IV-administered darinaparsin in lymphoma, particularly peripheral T-cell lymphoma ("PTCL"), at the American Society of Clinical Oncology (ASCO) in May of 2009 which would serve as the basis for ongoing clinical study in PTCL following regulatory review and available financial resources Phase I trials with the oral form are ongoing in both hematological malignancies and solid tumors.

Indibulin (ZybulinTM or ZIO-301) is a novel, oral tubulin binding agent that targets both mitosis and cancer cell migration. In addition, indibulin is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. In multiple Phase I trials in cancer patients, oral indibulin has been administered both as a single agent and in combination with favorable activity and a promising safety profile that does not include the neurotoxicity seen with all of the other classes of tubulin binding agents. Most recently, results of oral indibulin in combination with oral capecitabine (Xeloda®) were presented at last year's American Society of Clinical Oncology (ASCO) along with the preclinical findings of a novel dosing schedule conducted under the direction of Dr. Larry Norton; employing this dosage schedule, the Company has initiated a Phase I study in breast cancer patients with the Breast Cancer Medicine Service at Memorial Sloan-Kettering Cancer Center.

ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at www.ziopharm.com.

ZIOP-G

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, the risk that pre-clinical or clinical trials will proceed on schedules that are consistent with the Company's current expectations or at all, risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company's ability to obtain additional financing to support its operations thereafter. The Company assumes no obligation to update these forward-looking statements, except as required by law.

Contacts:

ZIOPHARM Oncology, Inc.
Tyler Cook, 617-259-1982
[e-mail]
or
Media:
Dennis S. Dobson, 203-258-0159
[e-mail]


© 2010 Business Wire

[NorbertHass]

Sollten nicht gestern oder heute Ergebnisse bekanntgegeben werden? War in einem Beitrag des Aktionär zu lesen?

Hat jemand eine Info, amerikanischer Kurs scheint ja auch noch nicht zu reagieren

[NorbertHass]

07.06.2010 21:30
ZIOPHARM Presents Positive Palifosfamide PICASSO Phase II Results in Oral Session at ASCO
Ads by Google

What is Pasireotide?
Learn of research trials to advance
patient care with pasireotide
www.pasporttrials.com/Pasireotide

Clinical Trial Solutions
Hosted or standalone IVR/IWR
for datacollection & randomisation
www.orcapharma.com
-- Randomized Phase III Expected to Commence Mid-Year --

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque and first author of the abstract, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)," (Abstract #10004) presented in an oral session today updated positive data from PICASSO. The presentation was part of the 46th Annual American Society of Clinical Oncology (ASCO) meeting being held in Chicago, IL, from June 4th to 8th. The abstract has also been selected as part of the 2010 Best of ASCO® which features high-impact abstracts from the ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today.

"The conclusions from the PICASSO study are that palifosfamide in combination with doxorubicin is well tolerated, easy to administer and can be given in the outpatient setting, and is active in soft tissue sarcoma," commented Dr. Verschraegen. "We look forward to the initiation of the pivotal Phase III study, which is designed based on the PICASSO study, and pending regulatory clearance by FDA through the Special Protocol Assessment process."

As previously announced, a total of 67 patients with soft tissue sarcoma (STS) were randomized with 66 treated and 62 eligible for evaluation. The study was powered to show a difference in progression free survival (PFS) between doxorubicin in combination with palifosfamide versus doxorubicin alone. The initial analysis demonstrated that the hazard ratio (HR) met the specified endpoint and after consultation with the Data Committee, independent sarcoma experts, and the Medical Advisory Board, enrollment was stopped and results were subsequently reported at the 2009 CTOS Annual Meeting. A second and subsequent analysis was conducted for an end-of-Phase-II meeting with the Food and Drug Administration (FDA) and those data were reported in the recently published ASCO abstract.

The updated study results presented to the FDA reported a hazard ratio of 0.43 favoring the palifosfamide combination with a statistically significant and clinically meaningful 3.4 month difference in median PFS. An analysis of the same data, presented today, consisting of those patients receiving either doxorubicin or doxorubicin in combination with palifosfamide for 6 cycles or less (the standard treatment period for doxorubicin) reported a hazard ratio of 0.39 (p= 0.023). This analysis also reported results for response rate -- for the palifosfamide doxorubicin combination 7 of 30 patients (23%) achieved a response, while for the doxorubicin arm alone; the response rate was 3 of 32 patients (9%). Preliminary survival data, based on a median follow-up of approximately 9 months, but with a number of patients still on study and data collection ongoing, showed a survival advantage trending in favor of the palifosfamide and doxorubicin combination over doxorubicin alone. Updated safety data showed there was similarity between the arms of the study. The most common grade 3+ events were neutropenia and elevated creatinine; both observed with similar frequency between treatment groups. There was no encephalopathy, hemorrhagic cystitis, nor Fanconi's Syndrome.

"We are very thankful to all who have contributed to the success of the PICASSO study and preparation for the initiation of the Phase III trial (PICASSO III)," added Jonathan Lewis, MD, PhD, of ZIOPHARM.


Quelle: Finanznachrichten.de